Xencor Management

Management criteria checks 2/4

Xencor's CEO is Bassil Dahiyat, appointed in Aug 1997, has a tenure of 26.75 years. total yearly compensation is $7.97M, comprised of 8.8% salary and 91.2% bonuses, including company stock and options. directly owns 0.4% of the company’s shares, worth €5.48M. The average tenure of the management team and the board of directors is 2.3 years and 7.1 years respectively.

Key information

Bassil Dahiyat

Chief executive officer

US$8.0m

Total compensation

CEO salary percentage	8.8%
CEO tenure	26.8yrs
CEO ownership	0.4%
Management average tenure	2.3yrs
Board average tenure	7.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bassil Dahiyat's remuneration changed compared to Xencor's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$8m	US$700k	-US$126m
Sep 30 2023	n/a	n/a	-US$119m
Jun 30 2023	n/a	n/a	-US$128m
Mar 31 2023	n/a	n/a	-US$140m
Dec 31 2022	US$8m	US$670k	-US$55m
Sep 30 2022	n/a	n/a	US$30m
Jun 30 2022	n/a	n/a	US$22m
Mar 31 2022	n/a	n/a	US$109m
Dec 31 2021	US$5m	US$625k	US$83m
Sep 30 2021	n/a	n/a	-US$4m
Jun 30 2021	n/a	n/a	US$24m
Mar 31 2021	n/a	n/a	-US$64m
Dec 31 2020	US$4m	US$600k	-US$69m
Sep 30 2020	n/a	n/a	-US$83m
Jun 30 2020	n/a	n/a	-US$80m
Mar 31 2020	n/a	n/a	-US$61m
Dec 31 2019	US$4m	US$567k	US$27m
Sep 30 2019	n/a	n/a	US$36m
Jun 30 2019	n/a	n/a	US$49m
Mar 31 2019	n/a	n/a	US$39m
Dec 31 2018	US$4m	US$550k	-US$70m
Sep 30 2018	n/a	n/a	-US$45m
Jun 30 2018	n/a	n/a	-US$71m
Mar 31 2018	n/a	n/a	-US$53m
Dec 31 2017	US$5m	US$525k	-US$38m

Compensation vs Market: Bassil's total compensation ($USD7.97M) is above average for companies of similar size in the German market ($USD1.61M).

Compensation vs Earnings: Bassil's compensation has increased whilst the company is unprofitable.

CEO

Bassil Dahiyat (53 yo)

26.8yrs

Tenure

US$7,965,955

Compensation

Dr. Bassil I. Dahiyat, Ph D., Co-founded Xencor, Inc. in August 1997 and has been its President and Chief Executive Officer since February 2005. Dr. Dahiyat serves as an Independent Director at Terray Ther...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Bassil Dahiyat	Co-Founder	26.8yrs	US$7.97m	0.40% $ 5.5m
John Desjarlais	Executive VP of Research & Chief Scientific Officer	9.8yrs	US$3.21m	0.23% $ 3.2m
Celia Eckert	Senior VP	4.7yrs	US$2.02m	0.030% $ 418.1k
Nancy Valente	Executive VP & Chief Development Officer	less than a year	US$5.35m	0.0015% $ 20.8k
Bart Cornelissen	Senior VP & CFO	less than a year	no data	no data
Charles Liles	Associate Director and Head of Corporate Communications & Investor Relations	no data	no data	no data
Jennifer Sandoz	Senior VIce President of Human Resources	2.8yrs	no data	no data
Jeremy Grunstein	Senior Vice President of Business Development	2.3yrs	no data	no data
Kirk Rosemark	Senior Vice President of Regulatory Affairs & Quality Assurance	2.3yrs	no data	no data
Eric Kowack	Senior Vice President of Program Leadership & Alliance Management	1.3yrs	no data	no data
Dane Leone	Senior VP of Corporate Strategy	less than a year	no data	no data

2.3yrs

Average Tenure

58yo

Average Age

Experienced Management: XE9's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Bassil Dahiyat	Co-Founder	26.8yrs	US$7.97m	0.40% $ 5.5m
Richard Ranieri	Independent Director	6.4yrs	US$347.02k	0% $ 0
Alan Montgomery	Independent Director	9.2yrs	US$384.19k	0% $ 0
Kevin Gorman	Independent Director	7.1yrs	US$342.50k	0% $ 0
Jeffrey Ravetch	Member of Scientific Advisory Board	14.9yrs	no data	no data
Ellen Feigal	Independent Director	5.5yrs	US$348.00k	0% $ 0
Kurt Gustafson	Independent Director	9.8yrs	US$346.50k	0.0097% $ 133.9k
Dagmar Rosa-Bjorkeson	Independent Director	4.4yrs	US$346.25k	0% $ 0
Barbara Klencke	Independent Director	less than a year	US$467.35k	no data

7.1yrs

Average Tenure

66yo

Average Age

Experienced Board: XE9's board of directors are considered experienced (7.1 years average tenure).

Xencor Management

Management criteria checks 2/4

Key information

Recent management updates

Xencor Appoints Bart Cornelissen as Senior Vice President

Co-Founder recently sold €270k worth of stock

Xencor, Inc. Appoints Dane Leone as Senior Vice President, Corporate Strategy

John J. Kuch to Retire as Chief Financial Officer of Xencor, Inc. in March 2024

Xencor Announces Planned Retirement of Senior Vice President John Kuch

Xencor, Inc. Appoints Barbara J. Klencke to Board of Directors

Recent updates

New minor risk - Shareholder dilution

Xencor Appoints Bart Cornelissen as Senior Vice President

Co-Founder recently sold €270k worth of stock

New minor risk - Profitability

Full year 2023 earnings released: US$2.08 loss per share (vs US$0.93 loss in FY 2022)

Xencor, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Xencor, Inc. Appoints Dane Leone as Senior Vice President, Corporate Strategy

Third quarter 2023 earnings released: US$0.40 loss per share (vs US$0.55 loss in 3Q 2022)

Xencor, Inc. to Report Q3, 2023 Results on Nov 07, 2023

John J. Kuch to Retire as Chief Financial Officer of Xencor, Inc. in March 2024

Xencor Announces Planned Retirement of Senior Vice President John Kuch

Xencor, Inc. Appoints Barbara J. Klencke to Board of Directors

Second quarter 2023 earnings released: US$0.37 loss per share (vs US$0.57 loss in 2Q 2022)

Xencor, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Xencor, Inc. Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress

Insufficient new directors

First quarter 2023 earnings released: US$1.02 loss per share (vs US$0.40 profit in 1Q 2022)

Co-Founder recently sold €172k worth of stock

Full year 2022 earnings released: US$0.93 loss per share (vs US$1.42 profit in FY 2021)

Xencor, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Senior VP & Chief Medical Officer recently sold €95k worth of stock

Xencor, Inc. Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma At the American Society of Hematology Annual Meeting

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$0.69 loss in 3Q 2021)

Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study

Xencor, Inc. to Report Q3, 2022 Results on Nov 07, 2022

High number of new directors

Xencor, Inc. to Present Seven Posters on Multiple Clinical Trials and Research-Stage Programs At the SITC Annual Meeting

High number of new directors

Xencbor, Inc. Announces the Appointment of Nancy Valente to Its Board of Directors

Second quarter 2022 earnings released: US$0.57 loss per share (vs US$0.90 profit in 2Q 2021)

Xencor, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Investor sentiment improved over the past week

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 2000 Growth-Defensive Index

Investor sentiment improved over the past week

Xencor, Inc. Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors

First quarter 2022 earnings released: EPS: US$0.40 (vs US$0.043 loss in 1Q 2021)

Co-Founder recently sold €65k worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Xencor, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting

Zenas BioPharma Limited acquired Exclusive worldwide rights to Obexelimab from Xencor, Inc. (NasdaqGM:XNCR).

Third quarter 2021 earnings released: US$0.69 loss per share (vs US$0.22 loss in 3Q 2020)

Director Yujiro Hata has joined 3rd company board

Second quarter 2021 earnings released: EPS US$0.90 (vs US$0.61 loss in 2Q 2020)

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 3000E Value Index

Sotrovimab Receives U.S. FDA Emergency Use Authorization for the Treatment of COVID-19

First quarter 2021 earnings released: US$0.043 loss per share (vs US$0.14 loss in 1Q 2020)

Xencor, Inc. Doses First Subject in Phase 1 Study of XMAB®564, an Engineered IL-2 Cytokine in Development for Autoimmune Diseases

Co-Founder recently sold €106k worth of stock

Xencor and UCLA Enter Collaboration to Discover and Develop Novel XmAb® Therapeutics

Full year 2020 earnings released: US$1.21 loss per share (vs US$0.47 profit in FY 2019)

Revenue beats expectations

Xencor, Inc. to Report Q4, 2020 Results on Feb 23, 2021

New 90-day high: €42.20

Xencor, Inc. and The University of Texas MD Anderson Cancer Center Enter Strategic Collaboration to Develop Novel T Cell-Engaging Bispecific Antibodies for Potential Treatment of Patients with Cancer

New 90-day high: €38.20

Senior VP & Chief Medical Officer recently sold €135k worth of stock

Miragen Therapeutics, Inc. Enters Technology License Agreement with Xencor, Inc

New 90-day high: €37.20

Xencor, MorphoSys AG and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab

Xencor Presents Updated Data From the DUET-2 Phase 1 Study of XmAb20717, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting

Revenue misses expectations

Third quarter 2020 earnings released: US$0.22 loss per share

Xencor to Present Data from Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia At the 2020 Ash Annual Meeting

Xencor, Inc. to Report Q3, 2020 Results on Nov 05, 2020

Xencor, Inc. to Present Data from the Phase 1 Study of XmAb 20717 and Three Research Programs at the SITC Annual Meeting

Xencor, Inc. Presents Initial Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at Nanets’ Multidisciplinary Net Medical Virtual Symposium

New 90-day high - €31.00

First half earnings released